{
  "trial_id": "NCT00330993",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "collected during the screening process will be destroyed.",
      "label": "met"
    },
    {
      "criterion": "Potential subjects interested in participation will be scheduled for a screening visit.",
      "label": "met"
    },
    {
      "criterion": "Each subject will undergo a minimum of 3 visits all of which will be performed in the Family Planning Research Office at Magee-Womens Hospital.",
      "label": "met"
    },
    {
      "criterion": "She will also receive a minimum of 3 follow-up telephone calls.",
      "label": "met"
    },
    {
      "criterion": "SCREENING AND ENROLLMENT: Visit length 1 \u00bd hours.",
      "label": "unknown"
    },
    {
      "criterion": "After obtaining consent for a screening ultrasound evaluation, a transvaginal and a transabdominal ultrasound examination will be performed to ascertain gestational age.",
      "label": "met"
    },
    {
      "criterion": "The transvaginal ultrasound results will be used to confirm gestational age and document an intrauterine gestation for the study protocol.",
      "label": "met"
    },
    {
      "criterion": "Vaginal ultrasound to confirm estimated gestational age (EGA) will use the following criteria: EGA (days) = mean sac diameter + 3025",
      "label": "unknown"
    },
    {
      "criterion": "Written informed consent will be obtained at the screening visit prior to any research activities.",
      "label": "met"
    },
    {
      "criterion": "A medical history and initial laboratory tests (hemoglobin and blood type) will be obtained.",
      "label": "met"
    },
    {
      "criterion": "If the pelvic examination is normal, the endovaginal ultrasound confirms that the gestational age will be less than 63 days on the day of the mifepristone administration, and the laboratory tests satisfy the entry criteria, the subject will be asked to participate in the study.",
      "label": "met"
    },
    {
      "criterion": "A HIPAA compliant 'Release of Medical Records' form will be signed to allow future access to medical records related to any care provided during the study by another health care provider.",
      "label": "unknown"
    },
    {
      "criterion": "VISIT 1: The subject will return prior to reaching 64 days gestation. This day will be considered Study Day 1. Visit length 30 minutes.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "treatment of an early pregnancy failure",
      "label": "triggers"
    },
    {
      "criterion": "contraindication to mifepristone (known allergy to mifepristone, chronic corticosteroid administration, adrenal disease)",
      "label": "unknown"
    },
    {
      "criterion": "contraindication to misoprostol (glaucoma, mitral stenosis, sickle cell anemia, poorly controlled seizure disorder, or known allergy to prostaglandin)",
      "label": "triggers"
    },
    {
      "criterion": "known or suspected extrauterine pregnancy",
      "label": "unknown"
    },
    {
      "criterion": "known or suspected pelvic infection",
      "label": "unknown"
    },
    {
      "criterion": "hemoglobin <10 mg/dL",
      "label": "triggers"
    },
    {
      "criterion": "known clotting defect or receiving anticoagulants",
      "label": "triggers"
    },
    {
      "criterion": "current breastfeeding",
      "label": "unknown"
    }
  ],
  "notes": "The patient is a healthy woman with no underlying disease. She has an irregular menstrual cycle and does not smoke or take any medications.",
  "_meta": {
    "topic_id": "33",
    "trial_id": "NCT00330993",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}